2581.HK
BenQ Medical Center faces mounting operational pressure as profits fall despite rising revenue

Intense competition and narrowing margins have caused the Taiwan-backed private hospital operator’s stock to plunge 70% below its IPO price less than a year ago

Key Takeaways:

  • BenQ Medical reported its revenue rose in the first three quarters of this year, but its profit tumbled by over 50%
  • The number of private hospitals in China shrank in 2025 for the first time in a decade

By Cheng Shui Tong

Hit by an oversupply in the private hospital market and stiff competition from public healthcare institutions, Chinese hospital stocks listed in Hong Kong have suffered steep declines across the board this year. Taiwan-backed BenQ BM Holding Cayman Corp. (2581.HK), which also goes by BenQ Medical, went public last December, and reflects the industry’s ailments. The private hospital operator’s stock plummeted 50% on its trading debut last year, making it the year’s worst first-day IPO performer, and has now shed more than 70% of its value.

A look at the numbers behind the company is cause for concern, with rising revenue and tumbling margins signaling shrinking profitability. BenQ parent Qisda Corp. recently released its financial results for the first three quarters of this year, showing that revenue from its BenQ Medical Center unit rose 11.5% year-on-year to T$9.53 billion ($290 million), while its profit for the same period plunged 57.1% to T$183 million.

The group’s midyear earnings showed its gross margin falling to 13.4% in the first half of the year from 15.9% a year earlier, primarily driven by higher depreciation and amortization expenses after the second phase of Nanjing BenQ Hospital commenced operations, resulting in rising staff costs from an expanded team of doctors and medical personnel.

It looks more like a trend than anomaly. While the company’s annual revenue has hovered around 2.6 billion yuan to 2.7 billion yuan ($390 million to $405 million) in recent years, its net profit has been on a steady downward trajectory.

Its net profit margin slid from 6.2% in 2023 to 4.1% in 2024 and 3.5% in 2025, before dropping further to just 1.9% in the first nine months of this year. Earning less than 2 yuan for every 100 yuan in revenue highlights just how razor-thin its margins have become, reflecting the broader operational headwinds facing private hospitals in China.

Making 2 yuan on every 100 yuan of business

As China’s economy grew, citizens became better able to afford pricier private healthcare services, fueling a rapid boom in private hospitals. In recent years, however, reckless expansion has led to a market glut and a subsequent wave of closures. In 2025, the total number of private hospitals saw a net decrease of about 1,000 from the previous year, marking the first contraction since 2015, with an estimated half of all private medical institutions operating in the red.

Data from the National Bureau of Statistics shows that while private hospitals numbered 26,000 at the end of 2025 — accounting for 70% of all hospitals nationwide — they handled only 16% of total patient visits. In other words, 70% of the country’s hospital count is fiercely competing for less than 20% of the patients, a classic case of too many providers chasing too few patients.

National healthcare policies in recent years have also proved unfavorable for private hospitals. For instance, the national medical insurance system has rolled out diagnosis-related groups (DRG) and diagnosis-intervention packet (DIP) payment models nationwide. Under these systems, treatments for the same condition are reimbursed at a bundled flat rate rather than on a fee-for-service basis. As a result, private hospitals can no longer pad bills through excessive testing and prolonged hospital stays, dealing an immediate blow to their bottom lines.

The central government has also stepped up inspections targeting non-compliant private hospitals. Coupled with the continuous expansion and improving service quality of public hospitals in recent years, more patients are gravitating toward the public healthcare system.

Taiwanese backing

Compared with other listed private hospitals, BenQ has a rather unique pedigree. Its controlling shareholder is Taiwan-listed Qisda, which primarily focuses on information technology and electronics. In the 2000s, founder Lee Kun-yao set up factories in cities such as Suzhou and Nanjing, employing over 10,000 workers. Noticing the scarcity of local medical resources when his employees sought healthcare, his idea was to build his own hospitals to care for both his staff and local residents. That vision aligned perfectly with the Nanjing municipal government’s desire at the time to bring in high-quality healthcare services.

In 2003, he brought in medical professionals from Taiwan to establish BenQ Medical Center, opening Nanjing BenQ Hospital in 2008 and Suzhou BenQ Hospital in 2013. In the early days, however, the Taiwanese medical staff struggled to adapt to the local environment and failed to manage the hospitals effectively, leaving the group mired in losses for years. It was only after implementing localization strategies in 2015 that the business gradually began to turn around.

After three attempts to list on the Hong Kong Stock Exchange, BenQ Medical Center finally went public last December. Riding the wave of a red-hot IPO market late last year, it priced its shares at a price-to-earnings (P/E) ratio of around 25 times — above the industry average — and was still over six times oversubscribed, raising more than HK$600 million ($76.5 million).

Following its debut, however, its valuation underwent a swift correction. The stock has since tumbled more than 70% from its offer price, bringing its P/E ratio down to a relatively reasonable level of around 9 times.

Among Chinese hospital stocks currently listed in Hong Kong, Guangdong Kanghua Healthcare Group (3689.HK) trades at a price-to-book (P/B) ratio of 0.35 times, while Concord Healthcare Group (2453.HK) sits at 0.24 times — both comparable to BenQ Medical. Meanwhile, private oncology hospital operator Hygeia Healthcare (6078.HK) commands a relatively higher P/B ratio of 0.89 times, reflecting its status as an industry leader with a scalable chain model that offers greater room for growth.

Growth constraints

BenQ Medical’s depressed valuation reflects its operational and geographic limitations, as well as its lack of nationwide scale. Although its markets in Nanjing and Suzhou are relatively affluent, both of its facilities are general hospitals operating in a fiercely competitive landscape.

Nanjing BenQ Hospital has stronger capabilities in emergency and critical care, whereas Suzhou BenQ Hospital specializes more in obstetrics and gynecology, pediatrics and geriatrics. With inpatient occupancy rates at both the Nanjing and Suzhou hospitals nearing saturation, future business expansion will hinge on the ramp-up of Nanjing BenQ Hospital’s second-phase facility and further foray into nursing homes to provide integrated services such as rehabilitation and long-term care.

Though BenQ Medical’s valuation has now fallen to a more-reasonable level, fierce market competition and constrained growth prospects leave little room for imagination. That makes it unlikely BenQ will find any near-term catalysts to spark a major rally in its share price.

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

51World prepares for Shenzhen listing

Hong Kong-listed digital twin technology company Beijing 51World Digital Twin Technology Co. Ltd. (6651.HK) said on Monday it has launched plans for a second listing on the Shenzhen Stock Exchange…